Double-blind Cross-over Trial of Flurbiprofen and Phenylbutazone in Ankylosing SpondylitisBr Med J 1974; 4 doi: https://doi.org/10.1136/bmj.4.5943.496 (Published 30 November 1974) Cite this as: Br Med J 1974;4:496
- A. Calin,
- R. Grahame
A double-blind cross-over study in 35 patients with ankylosing spondylitis was carried out comparing flurbiprofen (150 mg daily)—a new non-steroidal anti-inflammatory agent—with phenylbutazone (300 mg daily) over a four-week period. Flurbiprofen was well tolerated and shown to have therapeutic efficacy approaching that of phenylbutazone. The results suggest that flurbiprofen may prove a valuable alternative in the treatment of ankylosing spondylitis, and longterm efficacy and tolerance studies are clearly indicated.